The royalty-free cell lines are based on biopharmaceutical CHO platform of DG44 and K1 cell lines.
New cell lines fitting clinical and commercial production, are optimized for improved ADCC activity, adjusted galactosylation levels and amplified production of the target antibodies or proteins.
CHO production cell lines can be integrated with stable expression vector system and chemically defined media platform and also can be incorporated into on hand protein producer cell lines.
The company offers CHO cells with the modifications such as GlymaxX technology, Galactosylation Adjustment Technology and Pathway Modulator Technology.